Three-Year RCT of Genotropin in GH-Deficient Men with Stable CAD

Reading Time: 2 minutes

Introduction
Coronary artery disease (CAD) remains the leading cause of morbidity and mortality among American males, with an estimated 10.2 million prevalent cases in men aged 45 years and older, according to the Centers for Disease Control and Prevention (CDC) 2023 data. Growth hormone (GH) deficiency, often comorbid in aging males with CAD, contributes to endothelial dysfunction, dyslipidemia, and left ventricular (LV) remodeling. Genotropin®, a recombinant human GH (rhGH), has shown promise in restoring anabolic pathways, improving insulin-like growth factor-1 (IGF-1) levels, and modulating inflammation. This three-year prospective study evaluates the efficacy and safety of subcutaneous Genotropin therapy (0.3-0.5 mg/day, titrated to IGF-1 normalization) in 248 American males (mean age 56.4 ± 8.2 years) diagnosed with stable CAD via coronary angiography (≥50% stenosis in ≥1 major vessel). Participants, recruited from 12 U.S. cardiology centers (Midwest and Southeast regions), were randomized 1:1 to Genotropin (n=124) or placebo (n=124), alongside standard CAD pharmacotherapy (statins, antiplatelets, beta-blockers). Primary endpoints included changes in LV ejection fraction (LVEF) by echocardiography, carotid intima-media thickness (CIMT) via ultrasound, and high-sensitivity C-reactive protein (hs-CRP). Secondary outcomes encompassed lipid profiles, exercise tolerance (6-minute walk test), and major adverse cardiovascular events (MACE: myocardial infarction, stroke, revascularization).

Study Methodology
Eligible participants were community-dwelling U.S. males of non-Hispanic White (68%), Hispanic (18%), and Black (14%) descent, with confirmed GH deficiency (IGF-1 <100 ng/mL) and New York Heart Association class I-II symptoms. Exclusion criteria included active malignancy, uncontrolled diabetes (HbA1c >8.5%), or prior GH exposure. Baseline assessments occurred at enrollment (2020-2021), with follow-ups at 6, 12, 24, and 36 months. Genotropin dosing was individualized using serum IGF-1 monitoring to avoid supraphysiological levels (>2 SD above age-matched norms). Multimodal imaging included cardiac MRI for myocardial viability and CT angiography for plaque volume quantification. Statistical analyses employed mixed-effects models for longitudinal data, adjusting for age, BMI (mean 29.8 ± 4.5 kg/m²), smoking history (42% ever-smokers), and baseline LVEF (48.2 ± 7.1%). Intention-to-treat analysis used a p<0.05 significance threshold, powered at 90% to detect a 5% LVEF improvement. Key Results
Genotropin therapy yielded significant cardiovascular benefits. LVEF improved by 8.4% (from 48.2% to 56.6%; p<0.001) in the treatment arm versus 1.2% (p=0.42) in placebo at 36 months, corroborated by cardiac MRI (end-diastolic volume reduction: -12.3 mL/m², p=0.002). CIMT regressed by 0.11 mm (95% CI: -0.15 to -0.07; p<0.001), with CT angiography revealing 18% less coronary plaque progression (p=0.01). Inflammatory markers declined: hs-CRP fell 42% (3.2 to 1.9 mg/L; p<0.001), interleukin-6 by 29% (p=0.003). Lipid improvements included LDL-cholesterol reduction (-22 mg/dL; p<0.001) and HDL increase (+9 mg/dL; p=0.01). Exercise capacity rose 68 meters on the 6-minute walk test (p<0.001). MACE rates were lower (4.8% vs. 12.1%; HR 0.38, 95% CI 0.17-0.85; p=0.02). Adverse events were mild: peripheral edema (15%), arthralgia (11%), and transient hyperglycemia (8%), resolving with dose adjustment; no increased neoplasm risk (cancer incidence 2.4% vs. 3.2%). Discussion
These findings underscore Genotropin's role in reversing GH deficiency-associated cardiometabolic derangements in American males with CAD. Mechanistically, rhGH upregulates nitric oxide synthase, enhances collagen turnover, and promotes reverse cholesterol transport, mitigating LV systolic dysfunction and atherogenesis—effects amplified in obese cohorts (BMI >30 kg/m² subgroup: LVEF gain 10.2%). Compared to prior trials (e.g., RIGHD study showing modest IGF-1 benefits), this U.S.-centric cohort highlights ethnic diversity influences, with stronger hs-CRP reductions in Black participants (p=0.04 interaction). Limitations include modest sample size per subgroup, lack of hard mortality endpoints, and potential selection bias toward motivated urban males. Nonetheless, the prospective design and rigorous endpoints affirm clinical relevance, aligning with American Heart Association guidelines on adjunctive therapies for high-risk CAD.

Conclusion and Clinical Implications
Genotropin therapy over three years safely improves LV function, attenuates vascular inflammation, and curtails MACE in GH-deficient American males with CAD. For U.S. clinicians, IGF-1 screening in CAD patients aged 45-65 could identify candidates, potentially reducing the $219 billion annual CAD burden (AHA 2023). Larger trials validating hard outcomes and cost-effectiveness are warranted to integrate rhGH into personalized cardiology protocols.

(Word count: 672)